Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Bashinformsvyaz reported for 6 months of 2023 by IFRS

8/29/23 BISVP

Aeroflot reported for 6 months of 2023 by IFRS

8/29/23 AFLT

United Medical reported for 6 months of 2023

8/29/23 GEMC

Inter RAO reported for 6 months of 2023 by IFRS

8/29/23 IRAO

TCS Group reported for 6 months of 2023 by IFRS

8/29/23 T

Lukoil reports for 6 months of 2023 by IFRS

8/29/23 LKOH

TNS Energy Mari El reported for 6 months of 2023 by IFRS

8/29/23 MISB

TNS Energo Nizhny Novgorod reported for 6 months of 2023 by IFRS

8/29/23 NNSB

YTEK reported for 6 months of 2023 by IFRS

8/29/23 YAKG

Kaluga Sales Company reported for 6 months of 2023 by IFRS

8/29/23 KLSB